About NextCell | NextCell Pharma AB

Business concept

NextCell's business concept is to develop and commercialize mesenchymal stromal cell products based on the company's patented selection algorithm, primarily for the treatment of autoimmune type 1 diabetes, alongside other types of autoimmune and inflammatory diseases.

NextCell's pivotal drug candidate is ProTrans, developed initially for the treatment of type 1 diabetes. Both safety and efficacy in preserving the patients' ability to produce their own insulin have been demonstrated in clinical drug trials.

Cellaviva is the largest private stem cell bank in Scandinavia. Through Cellaviva, expectant parents are provided with the opportunity to preserve and store their newborn child's stem cells for potential future medical needs of both the child and the family.

Vision

Pioneering cell therapy development for thetreatment of autoimmune and inflammatorydisorders.

‍

Mission

Lead the way in the development of next generation off-the-shelf cell therapies for treatment of autoimmune and inflammatory disorders.

Strategy

Short term

To show the safety and efficacy of ProTrans in children, adolescents and adults newly diagnosed with type 1 diabetes
To secure production facility capabilities in several sites
To secure the regulatory pathways for marketing authorisation approval

‍Long term

To take ProTrans to market for the indication of type 1 diabetes in a patient populationthat includes children, adolescents, and adults
To continue to build the platform technology to find new treatments for other inflammatory disorders that are currently lacking effective treatments with safety and efficacy

History

NextCell was founded in 2014 by CEO Dr. Mathias Svahn, two current board members; Professor Edvard Smith and Hans-Peter Ekre, as well as Dr. Lena Degling Wilkingsson. The company was originally named Cellaviva AB. In 2016, a strategic decision was made to expand the operation and also conduct drug development and stromal cell research. At this point the company changed its name to NextCell Pharma AB.

Organisation

Management

Mathias Svahn

CEO

Born in 1976. Ph.D. and co-founder, background as scientific manager at KI and country medical manager at Roche. Joined NextCell Pharma in 2015. Holdings in NextCell Pharma as of August 31, 2024: 1,034,184 shares and 624,179 TO 2.

Patrik Fagerholm

CFO

Born in 1967. M. Sc. in Finance and Business Administration. Responsible for the financial operations. Joined NextCell Pharma in 2021. Holdings as of August 31, 2024: 106,360 shares and 89,760 TO 2.

Lindsay Davies

CSO

Born in 1979. PhD with a long experience in stromal cell biology and development of cell therapies. In the role as CSO, Davies is responsible for the existing research portfolio as well as the development of new clinical treatments. Lindsay Davies joined NextCell Pharma in 2020. Holdings in NextCell Pharma as of August 31, 2024: 0 shares.

Edvard Smith

Medical director

Born in 1951. MD, professor, co-founder and medically responsible for NextCell Pharma AB and Cellaviva. Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet and Karolinska University Hospital, Huddinge. His research has resulted in the identification of several disease genes and to new treatments. Edvard Smith joined NextCell Pharma in 2014. Holdings in NextCell Pharma as of August 31, 2024: 333,028 shares and 183,253 TO 2.

Sofie Falk Jansson

Head of Cellaviva

Born in 1986. Experienced marketeer within business to consumer. Joined NextCell Pharma in 2018. Holdings as of August 31, 2024: 12, 651 shares and 7.585 TO 2.

Sofia Sisay

Head of Clinical Trials

Born in 1981, Sofia Sisay possesses a PhD in Neuroscience, accompanied by a significant track record in orchestrating clinical studies and projects across both academic and industrial domains. In her role as Clinical Trial Manager, Sisay holds responsibility for the oversight of all ongoing clinical trials and has been entrusted with project leadership since the inception of NextCell's inaugural clinical trial. Sofia Sisay has been member of the NextCell Pharma team since the 2022. Holdings in NextCell Pharma as of August 31, 2024: 0 shares.

Board

Camilla Myhre Sandberg

Board member

Born in 1967. Independent of the Company and its principal owners. Board member with a marketing background in cell therapy and regenerative medicine, CEO at Miris Holding AB. Board member since 2017. Holdings in NextCell Pharma as of August 31, 2024: 0 shares.

Edvard Smith

Board member

Born in 1951. Independent of the Company´s principal owner. Member of the Management as Medical Director. Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet and Karolinska University Hospital, Huddinge. His research has resulted in the identification of several disease genes and to new treatments. Board member since 2014. Holdings in NextCell Pharma as of August 21, 2024: 333,028 shares and 183,253 TO2.

Hans-Peter Ekre

Chairman of the Board

Born in 1950. Independent of the Company and its principal owners. Background as investment manager at Karolinska Development and R&D manager at KabiPharmacia and Astra. Executive Chariman of the Board at Bactavia AB. Board member since 2014. Holdings in NextCell Pharma as of August 31, 2024: 324,042 shares and 184,07 TO 2.

Medical Advisers

Edvard Smith

MD, professor, co-founder and medically responsible for NextCell Pharma AB and Cellaviva since 2014. Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet and Karolinska University Hospital, Huddinge. His research has resulted in the identification of several disease genes and to new treatments.

Gunvor Ekman-Ordeberg

Professor in Obstetrics and gynecology at Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.

Per-Ola Carlsson

Professor in Medical Cell biology and experimental endocrinology at the Department of Medical Sciences, Transplantation and Regenerative medicine, Akademiska University Hospital, Uppsala, Sweden.

Timo Otonkoski

Professor of Medical Stem Cell Research, Children’s Hospital and Biomedicum Stem Cell Center, Program of Molecular Neurology, University of Helsinki, Helsinki, Finland

Xiao-Dong Chen

Professor and VA Research Health Scientist; Chief, Regenerative Medicine Program; Department of Physiology, University of Texas Health Science Center, San Antonio, USA

Company Structure

NextCell Pharma AB is the parent company for NextCell Pharma Group. NextCell has two daughter companies, Cellaviva AB and Qvance AB and also owns 8.5% of the shares in FamicordTx.